XLO Overview

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing masked immuno-oncology, or I-O, therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. Its pipeline products include Vilastobart, Efarindodekin alfa, XTX501, and masked T cell engagers. Vilastobart is an investigational masked, Fc-enhanced anti-CTLA-4 designed to block CTLA-4 and deplete regulatory T cells when activated (unmasked) in the tumor microenvironment (TME). XTX501 is a novel bispecific PD-1 / masked IL-2 designed to selectively stimulate PD-1 positive, antigen-experienced T cells and enhance their function. Its masked T cell engager programs consist of PSMA and STEAP1 with co-stimulation and CLDN18.2. The masked T cell engagers include molecules with one or more tumor-associated antigen (TAA) binding domains and a CD3 targeting domain.

Wall Street analysts forecast XLO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XLO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Xilio Therapeutics Inc revenue for the last quarter amounts to 13.69M USD, increased 693.85

Xilio Therapeutics Inc. EPS for the last quarter amounts to 0.95 USD, decreased -133.57

Xilio Therapeutics Inc (XLO) has 76 emplpoyees as of May 11 2026.

Today XLO has the market capitalization of 46.31M USD.